亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study

杜瓦卢马布 医学 奥西默替尼 不良事件通用术语标准 临床终点 回顾性队列研究 内科学 肿瘤科 危险系数 肺癌 比例危险模型 队列 不利影响 癌症 置信区间 腺癌 随机对照试验 无容量 免疫疗法 ROS1型
作者
Amin H. Nassar,So Yeon Kim,Jacqueline V. Aredo,Jamie Feng,Frances A. Shepherd,Chao Xu,David Kaldas,Jhanelle E. Gray,Thomas J. Dilling,Joel W. Neal,Heather A. Wakelee,Yufei Liu,Steven H. Lin,Tariq Abuali,Arya Amini,Yunan Nie,Tejas Patil,Anastasiya Lobachov,Jair Bar,Bailey Fitzgerald,Yu Fujiwara,Thomas U. Marron,Rohit Thummalapalli,Helena A. Yu,Dwight H. Owen,John Sharp,Saira Farid,Pedro Rocha,Edurne Arriola,Angelica D’Aiello,Haiying Cheng,Ryan M. Whitaker,Kaushal Parikh,Yash P. Ashara,Luxi Chen,K. Nathan Sankar,Jeremy P. Harris,Misako Nagasaka,Adanma Ayanambakkam,Ana I. Velazquez Mañana,Meera Vimala Ragavan,Jessica J. Lin,Zofia Piotrowska,M. Wilgucki,Joshua E. Reuss,H Lüders,Christian Grohé,Javier Espinar,Ellina Cheskis Feiner,Salman R Punekar,Shruti Gupta,Ticiana Leal,David J. Kwiatkowski,Raymond H. Mak,Elio Adib,Abdul Rafeh Naqash,Sarah B. Goldberg
出处
期刊:Journal of Thoracic Oncology [Elsevier]
标识
DOI:10.1016/j.jtho.2024.01.012
摘要

Introduction Durvalumab improves survival when used as consolidation therapy after chemoradiation (CRT) in patients with stage III NSCLC. However, the optimal consolidation therapy for patients with EGFR-mutant (EGFRmut) stage III NSCLC remains unknown. Methods In this multi-institutional international retrospective analysis across 24 institutions, we evaluated outcomes in patients with stage III EGFRmut NSCLC treated with concurrent CRT followed by consolidation therapy with osimertinib, durvalumab, or observation between 2015 and 2022. Kaplan-Meier method was used to estimate real-world progression-free survival (rwPFS, primary endpoint) and overall survival (OS, secondary endpoint). Treatment-related adverse events (trAE) during consolidation treatment were defined using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Multivariable Cox regression analysis was used. Results Of 136 patients with stage III EGFRmut NSCLC treated with definitive concurrent CRT, 56 received consolidation durvalumab, 33 received consolidation osimertinib, and 47 received observation alone. Baseline characteristics were similar across the 3 cohorts. With a median follow-up of 46 months for the entire cohort, the median duration of treatment was not reached (NR) for osimertinib (Inter-quartile range [IQR]: NR-NR) and was 5.5 (IQR:2.4-10.8) months with durvalumab. After adjusting for nodal status, stage III A/B/C, and age, patients treated with consolidation osimertinib had significantly longer 24-month rwPFS compared to those in the durvalumab or observation cohorts (osimertinib: 86%, durvalumab: 30%, observation: 27%, p<0.001 for both comparisons). There was no difference in rwPFS between durvalumab and the observation cohort. No significant difference in OS across the 3 cohorts was detected, possibly due to the limited follow-up. Any grade trAE occurred in 52% (2 [6.1%] grade ≥3) and 48% (10 [18%] grade ≥3) of patients treated with osimertinib and durvalumab, respectively. Of 45 patients who progressed on consolidation durvalumab, 37 (82%) subsequently received EGFR tyrosine kinase inhibitors (TKIs). Of these, 14 (38%) patients developed trAEs including 5 pneumonitis (14%; 2 [5.4%] grade ≥3) and 5 diarrhea (14%; 1 [2.7%] grade ≥3). Conclusions This study suggests that among patients with stage III unresectable NSCLC with a sensitizing EGFR mutation, consolidation osimertinib was associated with significantly longer rwPFS than durvalumab or observation. No unanticipated safety signals were observed with consolidation osimertinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1分钟前
sciences发布了新的文献求助10
1分钟前
克偃统统完成签到,获得积分10
2分钟前
3分钟前
godfrey发布了新的文献求助50
4分钟前
Wang完成签到 ,获得积分20
4分钟前
4分钟前
4分钟前
打打应助超帅的龙猫采纳,获得30
5分钟前
nannan完成签到 ,获得积分10
5分钟前
研友_X894JZ完成签到 ,获得积分10
8分钟前
9分钟前
如沐春风发布了新的文献求助10
9分钟前
lixuebin完成签到 ,获得积分10
9分钟前
SciGPT应助如沐春风采纳,获得10
9分钟前
星辰大海应助Wei采纳,获得10
10分钟前
科研通AI2S应助科研通管家采纳,获得10
10分钟前
科目三应助科研通管家采纳,获得10
10分钟前
10分钟前
Thermalwave完成签到 ,获得积分10
10分钟前
492357816完成签到,获得积分10
10分钟前
10分钟前
11分钟前
研友_8oBpRZ发布了新的文献求助10
12分钟前
SOLOMON应助hjybaba7采纳,获得80
12分钟前
12分钟前
Wei发布了新的文献求助10
12分钟前
理化发布了新的文献求助10
12分钟前
传奇3应助理化采纳,获得10
12分钟前
Perry完成签到,获得积分10
13分钟前
研友_8oBpRZ完成签到,获得积分10
13分钟前
try完成签到,获得积分10
13分钟前
研友_8oBpRZ发布了新的文献求助10
13分钟前
13分钟前
Wei发布了新的文献求助10
14分钟前
Joseph完成签到,获得积分10
16分钟前
牧沛凝完成签到,获得积分10
17分钟前
秋雪瑶应助牧沛凝采纳,获得10
17分钟前
韩学冲完成签到 ,获得积分10
18分钟前
hjybaba7发布了新的文献求助10
18分钟前
高分求助中
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Edestus (Chondrichthyes, Elasmobranchii) from the Upper Carboniferous of Xinjiang, China 500
Chinese-English Translation Lexicon Version 3.0 500
Electronic Structure Calculations and Structure-Property Relationships on Aromatic Nitro Compounds 500
マンネンタケ科植物由来メロテルペノイド類の網羅的全合成/Collective Synthesis of Meroterpenoids Derived from Ganoderma Family 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2380965
求助须知:如何正确求助?哪些是违规求助? 2088260
关于积分的说明 5244402
捐赠科研通 1815283
什么是DOI,文献DOI怎么找? 905736
版权声明 558834
科研通“疑难数据库(出版商)”最低求助积分说明 483664